Skip to content

Perspective Therapeutics CATX Operating Cash Flow

Operating Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$5.33B+220%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$25.55M-21.4%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
-$3.47M+38.7%
Immunome logo
ImmunomeIMNM
-$58.64M-10.5%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$119.65M-29.1%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$125.13M+16.3%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's operating cash flow?
Perspective Therapeutics (CATX) reported operating cash flow of -$31.47M in Q1 2026.
How has Perspective Therapeutics's operating cash flow changed year-over-year?
Perspective Therapeutics's operating cash flow decreased by 45.8% year-over-year, from -$21.58M to -$31.47M.
What is the long-term trend for Perspective Therapeutics's operating cash flow?
Over 3 years (2022 to 2025), Perspective Therapeutics's operating cash flow has grown at a 99.4% compound annual growth rate (CAGR), from -$10.4M to -$82.48M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.